Biotech startups that raised Series C in California, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| BigHat Biosciences | San Mateo | Series C | $75.0M | 2026-09-24 |
| Chai Discovery | San Francisco | Series C | $400.0M | 2026-07-14 |
| Cellanome | Redwood City | Series C | $75.9M | 2026-06-18 |
| Terremoto Biosciences | San Francisco | Series C | $108.0M | 2026-04-15 |
| Loyal | San Francisco | Series C | $100.0M | 2026-02-11 |
| Culture Biosciences | San Francisco | Series C | $80.0M | 2025-12-16 |
| Aspen Neuroscience | San Diego | Series C | $115.0M | 2025-11-20 |
| TORL BioTherapeutics | Culver City | Series C | $96.0M | 2025-10-07 |
8 rows of the CSV in 5 of its 18 columns.
- The 143 biotech startups in California, United States whose last round is Series C have raised $17.3B in total.
- 13 of them closed their most recent round in the last 12 months, $1.3B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Hexagon Bio's $62.0M Series C on 23 October 2026.
- Khosla Ventures is an investor in 6 of them, more than any other fund.
- Health care is the most common other sector, with 134 companies (94%).
- 4% were founded in 2020 or later; the median founding year is 2012.
- The most common team size is 11 to 50 employees (49% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
28 of 143| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Cellanome | Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. | Biotech | Redwood City | Series C | $75.9M | 2026-06-18 | $289.6M | Premji Invest, Synetro Group | 51 to 100 | 2020 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | San Francisco | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| TORL BioTherapeutics | TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. | Biotech | Culver City | Series C | $96.0M | 2025-10-07 | $412.0M | Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 | 51 to 100 | 2018 |
| Attovia Therapeutics | Attovia Therapeutics develops biotherapeutics for immune-mediated diseases. | Biotech | San Carlos | Series C | $90.0M | 2025-04-15 | $255.0M | Goldman Sachs Asset Management, Cormorant Asset Management, Marshall Wace +2 | 11 to 50 | 2023 |
| Biolinq | Biolinq develops a wearable biosensor platform that measures blood level information. | Biotech | San Diego | Series C | $100.0M | 2025-03-19 | $276.3M | Alpha Wave Global, Pegasus Tech Ventures, M Ventures | 51 to 100 | 2012 |
| ArsenalBio | ArsenalBio develops programmable CAR T-cell therapies for solid tumors. | Biotech | South San Francisco | Series C | $325.0M | 2024-09-04 | $630.8M | ARCH Venture Partners, Bristol-Myers Squibb, NVentures +1 | 251 to 500 | 2019 |
| Autobahn Therapeutics | Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. | Biotech | San Diego | Series C | $100.0M | 2024-07-24 | $208.7M | Insight Partners, Invus, Bristol-Myers Squibb +2 | 11 to 50 | 2017 |
| Bluejay Therapeutics | Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. | Biotech | San Mateo | Series C | $182.0M | 2024-05-09 | $242.2M | RA Capital Management, Wellington Management, Novo Holdings +2 | 11 to 50 | 2019 |
| Aardvark Therapeutics | Aardvark Therapeutics develops small molecule drugs for obesity and rare genetic metabolic disorders. | Biotech | San Diego | Series C | $85.0M | 2024-05-09 | $129.0M | Cormorant Asset Management, Vickers Venture Partners, Decheng Capital +1 | 11 to 50 | 2017 |
| Karius | Karius delivers genomic insights into infectious diseases to guide clinical treatment decisions. | Artificial intelligence | Redwood City | Series C | $100.0M | 2024-05-02 | $354.0M | Lightspeed Venture Partners, General Catalyst, Khosla Ventures +1 | 101 to 250 | 2014 |
| Endeavor BioMedicines | Endeavor BioMedicines develops treatments that target the underlying causes of pulmonary fibrosis. | Biotech | Solana Beach | Series C | $132.5M | 2024-04-24 | $295.5M | Fidelity, Invus, T. Rowe Price +2 | 11 to 50 | 2018 |
| Siolta Therapeutics | Siolta Therapeutics develops therapeutic microbial consortia to prevent and treat inflammatory diseases. | Biotech | San Carlos | Series C | $12.0M | 2024-03-12 | $42.0M | Khosla Ventures, Global Brain Corporation, Seventure Partners +1 | 1 to 10 | 2016 |
| Unlearn.AI | Unlearn.AI uses AI, digital twins, and statistical methods to enable smaller, more efficient clinical trials. | Artificial intelligence | San Francisco | Series C | $50.0M | 2024-02-08 | $134.8M | Alumni Ventures, Insight Partners, 8VC +2 | 51 to 100 | 2017 |
| Aizon | Aizon provides a cloud-based SaaS platform that improves industrial processes in biotech and pharma. | Artificial intelligence | San Francisco | Series C | $20.0M | 2024-02-07 | $44.8M | 500 Global, FundersClub, Uncork Capital +2 | 101 to 250 | 2013 |
| Koya Medical | Koya Medical develops treatments for lymphedema and venous diseases. | Biotech | Oakland | Series C | $30.0M | 2023-11-15 | $70.2M | National Science Foundation, MedTech Innovator, OrbiMed +2 | 101 to 250 | 2018 |
| Atomica Corp | Atomica Corp operates the largest US MEMS foundry, producing photonics, sensors, and microfluidic biochips. | Biotech | Santa Barbara | Series C | $30.0M | 2022-11-08 | $74.4M | Scale Venture Partners, Miramar Ventures, Agility Capital +1 | 101 to 250 | 2000 |
| NovaSignal | NovaSignal commercializes a robotic system for cerebral ultrasound imaging. | Artificial intelligence | Los Angeles | Series C | $37.0M | 2021-09-28 | $127.9M | MassChallenge, National Science Foundation, TCA Venture Group +2 | 51 to 100 | 2013 |
| InterVenn | InterVenn uses artificial intelligence to study the glycoproteome for diagnostic and therapeutic healthcare solutions. | Artificial intelligence | South San Francisco | Series C | $201.0M | 2021-08-02 | $244.4M | True Ventures, Boost VC, Anzu Partners +2 | 51 to 100 | 2017 |
| Helix | Helix is a population genomics company that advances genomics research and integrates genomic data into clinical care. | Biotech | San Mateo | Series C | $50.0M | 2021-06-03 | $403.0M | Temasek, Warburg Pincus, Sutter Hill Ventures +1 | 101 to 250 | 2015 |
| Insitro Unicorn | Insitro applies machine learning and biology to drug discovery and development. | Artificial intelligence | South San Francisco | Series C | $400.0M | 2021-03-15 | $643.0M | Temasek, BlackRock, ARCH Venture Partners +1 | 251 to 500 | 2018 |
| Vineti | Vineti provides a cloud-based platform that helps patients access cell and gene therapies. | Biotech | Oakland | Series C | $33.0M | 2020-10-13 | $115.2M | S32, Casdin Capital | 101 to 250 | 2016 |
| Fetch Robotics | Fetch Robotics provides cloud-driven autonomous mobile robots for warehouse intralogistics. | Biotech | San Jose | Series C | $46.0M | 2019-07-23 | $94.0M | SoftBank, Shasta Ventures, Employee Stock Option Fund +2 | 51 to 100 | 2014 |
| Pionetics | Pionetics develops and manufactures drinking water purification systems. | Biotech | San Carlos | Series C | $3.0M | 2007-05-21 | $12.9M | RockPort Capital, Pangaea Ventures, Firelake Capital Management | 11 to 50 | 1995 |
Table 1. Biotech startups that raised Series C in California, United States: the 28 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 143.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 3 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 4 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 5 | Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | San Francisco | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| 6 | Cellanome | Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. | Biotech | Redwood City | Series C | $75.9M | 2026-06-18 | $289.6M | Premji Invest, Synetro Group | 51 to 100 | 2020 |
| 7 | BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
Table 2. Biotech startups that raised Series C in California, United States: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 6 | 4% | 2 | Prellis Biologics, Loyal |
| 2 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 5 | 3% | 1 | BigHat Biosciences |
| 3 | Y Combinator | Startup accelerator | Mountain View, United States | 5 | 3% | 1 | Culture Biosciences |
| 4 | OrbiMed | Private equity firm | New York, United States | 4 | 3% | 2 | Terremoto Biosciences, Aspen Neuroscience |
| 5 | RA Capital Management | Startup incubator | Boston, United States | 4 | 3% | ||
| 6 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 3 | 2% | 1 | Culture Biosciences |
| 7 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 3 | 2% | 1 | Aspen Neuroscience |
| 8 | Alumni Ventures | Angel group | Manchester, United States | 3 | 2% | ||
| 9 | 8VC | Venture capital firm | Austin, United States | 2 | 1% | 1 | BigHat Biosciences |
| 10 | Cantos | Micro VC fund | San Francisco, United States | 2 | 1% | 1 | Prellis Biologics |
| 11 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 2 | 1% | 1 | Terremoto Biosciences |
| 12 | EDBI | Venture capital firm | Singapore | 2 | 1% | 1 | Aspen Neuroscience |
| 13 | S32 | Venture capital firm | San Diego, United States | 2 | 1% | 1 | Aspen Neuroscience |
| 14 | Blue Owl | Private equity firm | New York, United States | 2 | 1% | ||
| 15 | Cormorant Asset Management | Hedge fund | Boston, United States | 2 | 1% |
Table 3. Biotech startups that raised Series C in California, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 134 | 94% | $16.2B |
| Software | 22 | 15% | $4.5B |
| Artificial intelligence | 11 | 8% | $2.8B |
| Hardware | 8 | 6% | $1.1B |
| Fintech | 4 | 3% | $543.0M |
| Energy | 1 | 1% | $37.4M |
Table 4. Biotech startups that raised Series C in California, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 143 | 100% | $35.0M |
Table 5. Biotech startups that raised Series C in California, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 26 | 18% |
| San Diego | 26 | 18% |
| Menlo Park | 12 | 8% |
| South San Francisco | 8 | 6% |
| San Carlos | 6 | 4% |
| San Mateo | 5 | 3% |
| Redwood City | 5 | 3% |
| Mountain View | 5 | 3% |
| Irvine | 5 | 3% |
| Los Angeles | 4 | 3% |
| Hayward | 4 | 3% |
| Oakland | 3 | 2% |
Table 6. Biotech startups that raised Series C in California, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 8% | $62.0M |
| September 2026 | 1 | 8% | $75.0M |
| July 2026 | 2 | 15% | $409.0M |
| June 2026 | 1 | 8% | $75.9M |
| May 2026 | 1 | 8% | |
| April 2026 | 1 | 8% | $108.0M |
| March 2026 | 1 | 8% | $22.0M |
| February 2026 | 1 | 8% | $100.0M |
| January 2026 | 2 | 15% | $245.0M |
| December 2025 | 1 | 8% | $80.0M |
| November 2025 | 1 | 8% | $115.0M |
Table 7. Biotech startups that raised Series C in California, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 11 | 8% | $1.1B |
| 2025 | 11 | 8% | $890.2M |
| 2024 | 17 | 12% | $1.3B |
| 2023 | 6 | 4% | $333.0M |
| 2022 | 9 | 6% | $922.9M |
| 2021 | 10 | 7% | $1.2B |
Table 8. Biotech startups that raised Series C in California, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 2 | 1% |
| 2020 to 2022 | 4 | 3% |
| 2015 to 2019 | 44 | 31% |
| 2010 to 2014 | 35 | 25% |
| Before 2010 | 57 | 40% |
Table 9. Biotech startups that raised Series C in California, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 13 | 9% |
| 11 to 50 | 69 | 49% |
| 51 to 100 | 27 | 19% |
| 101 to 250 | 22 | 16% |
| 251 to 500 | 4 | 3% |
| 501 to 1,000 | 1 | 1% |
| 1,001 to 5,000 | 1 | 1% |
| 5,001 to 10,000 | 1 | 1% |
| 10,001 or more | 2 | 1% |
Table 10. Biotech startups that raised Series C in California, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in California, United States. On 16 November 2026 that is 143 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 28 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 143 rows: 6 have no round amount, 0 no city and 8 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in California, United States whose last round is Series C are on the list?
- 143, in the file dated 16 November 2026. 13 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 143 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.